China's EpimAb Advances Bispecific Antibody To Rival Janssen Candidate

EpimAb's business development officer tells Scrip dosing has started in a Phase I/II trial assessing the China-based biotech's lead cancer molecule EMB01, an EGFR-cMET bispecific antibody.

Success
EpimAb is using its platform to develop a pipeline of bispecific antibodies • Source: Shutterstock

China-based EpimAb Biotherapeutics has successfully progressed its lead cancer asset - a bispecific antibody that simultaneously targets EGFR and cMET - into Phase I/II trials. The start-up is on track with its plan to build a proprietary pipeline organically, using its FIT-Ig (Fabs-In-Tandem Immunoglobulin) platform, its chief operating and chief business officer told Scrip.

EMB01 is a bispecific antibody that simultaneously targets epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET), two validated...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Start-Ups & SMEs

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.